Tachycardia-induced metabolic rewiring as a driver of contractile dysfunction

Chengyi Tu,Arianne Caudal,Yu Liu,Nikoloz Gorgodze,Hao Zhang,Chi Keung Lam,Yuqin Dai,Angela Zhang,Alexa Wnorowski,Matthew A. Wu,Huaxiao Yang,Oscar J. Abilez,Xuchao Lyu,Sanjiv M. Narayan,Luisa Mestroni,Matthew R. G. Taylor,Fabio A. Recchia,Joseph C. Wu
DOI: https://doi.org/10.1038/s41551-023-01134-x
IF: 28.1
2023-11-28
Nature Biomedical Engineering
Abstract:Prolonged tachycardia—a risk factor for cardiovascular morbidity and mortality—can induce cardiomyopathy in the absence of structural disease in the heart. Here, by leveraging human patient data, a canine model of tachycardia and engineered heart tissue generated from human induced pluripotent stem cells, we show that metabolic rewiring during tachycardia drives contractile dysfunction by promoting tissue hypoxia, elevated glucose utilization and the suppression of oxidative phosphorylation. Mechanistically, a metabolic shift towards anaerobic glycolysis disrupts the redox balance of nicotinamide adenine dinucleotide (NAD), resulting in increased global protein acetylation (and in particular the acetylation of sarcoplasmic/endoplasmic reticulum Ca 2+ -ATPase), a molecular signature of heart failure. Restoration of NAD redox by NAD + supplementation reduced sarcoplasmic/endoplasmic reticulum Ca 2+ -ATPase acetylation and accelerated the functional recovery of the engineered heart tissue after tachycardia. Understanding how metabolic rewiring drives tachycardia-induced cardiomyopathy opens up opportunities for therapeutic intervention.
engineering, biomedical
What problem does this paper attempt to address?